BridgeMD
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: a single-arm interventional clinical trial. Study 2: Patients on the waiting list for kidney transplantation.
EU CTIS ID: 2023-506436-33-00
What this study is testing
To evaluate whether 3 to 6 months treatment with GLP-1 RA in patients on the RT waiting list with metabolic syndrome (defined by meeting 2 or more criteria of: prediabetes, abdominal obesity, hypertriglyceridemia and/or dyslipidemia) reverse metabolic syndrome before RT - evaluating the status after 3 and 6 months after having started the medication - (reversing the metabolic syndrome) after 3 and, if possible, 6 months of treatment.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients on the RT waiting list
- Over 18 years
- Women of childbearing potential must use effective contraceptive measures during their participation in the study.
- With metabolic syndrome defined by 2 or more of the following criteria (National Cholesterol Education Program Adult Treatment Panel III guidelines (7) adjusted for: (a) pre-diabetes as determined by: fasting plasma glucose of 100-126 mg/dL (5.6-6.9 mmol/L ), and/or impaired fasting glucose <126 mg/dL (7 mmol/L) with 2 h plasma glucose after an oral glucose of 140-200 mg/dL (7.8-11 mmol/L) and/or HbA1c 5.7-6.4%) (b) obesity as defined by: waist circumference greater than 102 cm (men) or 88 cm (women) c) triglycerides ≥150 mg/dL d) HDL cholesterol < 40mg/dL in men or < 50mg/dL in women
You likely can't join if
- Under 18 years of age,
- previously diagnosed diabetes,
- Hepatic Failure
- history of pancreatitis (acute or chronic),
- síndrome de neoplasia endocrina múltiple tipo 2 (MEN 2)
- personal or family history of medullary thyroid carcinoma (MTC),
See the full eligibility criteria
- Patients on the RT waiting list
- Over 18 years
- Women of childbearing potential must use effective contraceptive measures during their participation in the study.
- With metabolic syndrome defined by 2 or more of the following criteria (National Cholesterol Education Program Adult Treatment Panel III guidelines (7) adjusted for: (a) pre-diabetes as determined by: fasting plasma glucose of 100-126 mg/dL (5.6-6.9 mmol/L ), and/or impaired fasting glucose <126 mg/dL (7 mmol/L) with 2 h plasma glucose after an oral glucose of 140-200 mg/dL (7.8-11 mmol/L) and/or HbA1c 5.7-6.4%) (b) obesity as defined by: waist circumference greater than 102 cm (men) or 88 cm (women) c) triglycerides ≥150 mg/dL d) HDL cholesterol < 40mg/dL in men or < 50mg/dL in women
- Under 18 years of age,
- previously diagnosed diabetes,
- Hepatic Failure
- history of pancreatitis (acute or chronic),
- síndrome de neoplasia endocrina múltiple tipo 2 (MEN 2)
- personal or family history of medullary thyroid carcinoma (MTC),
- pregnant or lactating women
- moderate to severe pre-existing gastroparesis.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.